Navigation Links
Essilor's First-Half 2008 Results
Date:8/27/2008

/> http://hosting.3sens.com/Essilor/20080828-379EA2FD/en

The presentation will be posted at the following address:

http://www.essilor.com/results-presentations

Regulatory Information The interim report can be downloaded from the Company's website, http://www.essilor.com, in the News > Publications section, or by clicking on: http://www.essilor.com/reports#interim

------------------------

Next financial announcement:

Third-quarter revenue will be announced on Thursday, October 23, 2008.

------------------------

Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux(R), Crizal(R), Essilor(R) and Definity(R) brands to correct myopia, hyperopia, presbyopia and astigmatism. Essilor operates worldwide through 15 production sites, 270 lens finishing laboratories and local distribution networks. The Essilor share trades on the Euronext Paris market and is included in the CAC 40 index. Codes and symbols: ISIN: FR 0000121667; Reuters: ESSI.PA; Bloomberg: EF.FP.

------------------------

Management Report

First-Half 2008

EUR millions First-half 2008 First-half 2007 % change

Revenue 1,520.2 1,476.9 +2.9%

Contribution from 276.3 267.3 +3.4%

operations (1)

18.2% 18.1%

% of revenue

Operating profit 261.7 253.2 +3.4%

Profit attributabl
'/>"/>

SOURCE Essilor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Biopure Announces 2008 Third Quarter Financial Results
2. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
3. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008
6. Rosetta Genomics Reports Second Quarter 2008 Financial Results
7. VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance
8. Arno Therapeutics Announces Second Quarter 2008 Financial Results
9. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
10. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
11. Yongye Biotechnology International Announces Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, ... that a collaboration led by the Icahn School of ... the first comprehensive analysis of a diploid human genome ... and genome mapping. This study, published today in ... contiguous diploid human genome assembly obtained without using inference-based ...
(Date:6/29/2015)... , June 29, 2015 According ... (DNA, RNA, XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology ... & Pharmaceutical Companies, CRO) - Global Forecast to 2020", published ... $244.93 Million by 2020 from $107.56 Million in 2015, at ... T ables and 67 F igures ...
(Date:6/29/2015)... AMSTERDAM , June 29, 2015 ... technical and medical information products and services, today announced ... 2014. According to the 2014 Journal Citation Reports® (JCR) ... journal Impact Factors increase from 2013 to 2014, ahead ... journals occupied the top rank in 62 subject categories, ...
(Date:6/26/2015)... MA (PRWEB) , ... June 26, 2015 , ... ... U.S. Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded ... to as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This ...
Breaking Biology Technology:BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.521 02/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.514 04/2002 , ... , , , , ... , Cell type , Bacteria, ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.511 04/2002 , ... , , , , ... , Cell type , Bacteria, gram ...
Cached Biology Technology:Mycobacterium intracellulare 2Escherichia coli K12 2Escherichia coli K12 3Escherichia coli C600 2Escherichia coli C600 3
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... ARBOR, Mich. An early laboratory success is taking ... gland transplants that could one day prevent a currently ... The scientists were able to induce embryonic stem ... hormone essential to maintaining bone density. The laboratory results ...
... ANN ARBOR, Mich.---Brain implants that can more clearly record ... at the University of Michigan. The findings could eventually ... as Parkinson,s disease and paralysis. Neural electrodes must ... When the electrodes are implanted, the brain first reacts ...
... calling on Congress to support the Consistency, Accuracy, Responsibility ... (CARE bill), which would ensure that states set minimum ... bill (H.R. 3652) was introduced Sept. 28 in the ... "The introduction of the CARE bill ...
Cached Biology News:Stem cell success points to way to regenerate parathyroid glands 2A step toward better brain implants using conducting polymer nanotubes 2A step toward better brain implants using conducting polymer nanotubes 3SNM urges Congress to support CARE bill 2
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
... Pack provides optimized blocking and wash ... Clarifier: Ready-to-use wash solutions have been ... Coated Slides for Microarrays (Product Code ... Buffer: 1L • Microarray Post Hybridization ...
Biology Products: